Skip to main content

Market Overview

Krystal Biotech Prices Upsized $125 Million Capital Offering at $65/Share

  • Krystal Biotech Inc (NASDAQ: KRYS) has priced the previously announced underwritten public offering of 1.923 million common shares at $65/share, representing gross proceeds of $125 million. Underwriters having an option to purchase up to an additional 288 thousand shares.
  • Net proceeds from this offering together with its existing cash, cash equivalents, and short-term investments will be used to complete the ongoing pivotal trial of B-VEC for DEB and prepare for potential commercialization, advance the development of KB105 in TGM1-deficient ichthyosis, preclinical development of KB104 for Netherton syndrome, advance development of KB407 for cystic fibrosis, accelerate the Company's emerging respiratory pipeline, as well as for working capital and general corporate purposes.
  • The offering is expected to close by February 5.
  • KRYS shares are down 5.48% at $67.04 in the pre-market session on the last check Wednesday.

Related Articles (KRYS)

View Comments and Join the Discussion!

Posted-In: Biotech News Offerings Small Cap General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at